Nelipepimut-S plus GM-CSF vaccine

Drug Overview

Nelipepimut-S plus GM-CSF vaccine (commonly known by the trade name NeuVax) is an investigational, “off-the-shelf” cancer immunotherapy designed to prevent the recurrence of breast cancer in patients with low-to-intermediate levels of HER2 expression. This therapeutic vaccine consists of the E75 peptide, derived from the Human Epidermal Growth Factor Receptor 2 (HER2) protein, combined with the immune adjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF).

In the clinical landscape of March 2026, nelipepimut-S is recognized as a leader in the “secondary prevention” of cancer. Unlike traditional vaccines that prevent an initial infection, this vaccine is administered to patients who are currently in remission (disease-free) but remain at high risk for the cancer returning. By “priming” the patient’s own T-cells to recognize even trace amounts of HER2-expressing cells, the vaccine acts as a biological surveillance system to eliminate micro-metastatic disease before it can form a detectable tumor.

• Generic Name: Nelipepimut-S plus GM-CSF.
• Trade Name: NeuVax.
• Drug Class: Cancer Vaccine; Peptide Immunotherapy; HER2-targeted Therapy.
• Mechanism: Active immunization using the E75 peptide to stimulate CD8+ cytotoxic T-lymphocytes (CTLs).
• Route of Administration: Intradermal injection.
• FDA Approval Status: Investigational. As of March 2026, nelipepimut-S is not FDA-approved for commercial sale. It has been granted Fast Track designation for the treatment of early-stage breast cancer and continues to be evaluated in Phase 2 and Phase 3 clinical trials, particularly in combination with other immunomodulators.

What Is It and How Does It Work? (Mechanism of Action)

The vaccine works by teaching the patient’s immune system to identify a specific “molecular signature” of breast cancer cells.

1. The E75 Peptide (The Target)

The E75 peptide is a small fragment of the HER2 protein. While many breast cancers are “HER2-negative” by standard pathology tests, they often still express low levels of HER2 (now frequently referred to as HER2-low).

• Targeting the “Low-Expressors”: Nelipepimut-S is specifically designed for these HER2-low patients, who often do not qualify for blockbuster drugs like Herceptin (trastuzumab).
• MHC Class I Binding: The E75 peptide is highly effective at binding to HLA-A2 and HLA-A3 molecules on the surface of cells, which is the “display case” that T-cells check to see if a cell is cancerous.

2. GM-CSF (The Adjuvant)

Because the E75 peptide is small, the immune system might ignore it. GM-CSF is added to act as a “danger signal.”

• Dendritic Cell Recruitment: GM-CSF draws dendritic cells (the “generals” of the immune system) to the injection site.
• Antigen Presentation: These dendritic cells “eat” the E75 peptide and show it to T-cells, effectively sounding the alarm.

3. T-Cell Mobilization

The final result is the creation of a specialized army of CD8+ Cytotoxic T-lymphocytes. These T-cells circulate through the body; when they encounter a cell displaying the E75/HER2 marker, they release toxins to destroy that cell immediately.

FDA-Approved Clinical Indications

There are currently no FDA-approved indications for nelipepimut-S plus GM-CSF.

However, research in 2026 is heavily focused on the following high-risk populations:

• Adjuvant Breast Cancer (HER2-Low): Patients with Stage I–III breast cancer who have completed standard surgery, radiation, and chemotherapy but have a high risk of relapse.
• Triple-Negative Breast Cancer (TNBC): Patients who lack estrogen, progesterone, and high HER2 receptors. Early data suggests these patients may benefit significantly from the vaccine’s ability to target even low-level HER2.
• Ductal Carcinoma In Situ (DCIS): Investigated as a way to prevent non-invasive cancer from becoming invasive.

Dosage and Administration Protocols

The vaccine is administered in two distinct phases: the Primary Immunization Series (PIS) and the Booster Phase.

Clinical Efficacy and Research Results

The journey of nelipepimut-S has been marked by a shift toward combination therapy results in early 2026:

• The PRESENT Trial: An earlier Phase 3 trial did not show a benefit for all patients, which led researchers to narrow their focus to specific subgroups (like those with low HER2 and HLA-A2/A3 status).
• Trastuzumab Synergy: A landmark Phase 2b study showed that combining nelipepimut-S with trastuzumab (Herceptin) significantly reduced the risk of recurrence compared to trastuzumab alone. This “double-hit” on HER2 one using an antibody and one using a vaccine is now a major area of study.
• Immune Response Rates: Over 90% of patients in clinical trials develop a measurable T-cell response to the E75 peptide, proving the vaccine is biologically active even if the clinical outcome takes years to observe.

Safety Profile and Side Effects

One of the greatest advantages of nelipepimut-S is its safety. Because it is a targeted vaccine, it avoids the “shotgun” damage of chemotherapy.

Common Side Effects (>50%):

• Injection Site Reactions: Redness (erythema), swelling (induration), and itching at the site of the shot. This is actually a positive sign that the immune system is responding.
• Flu-like Symptoms: Mild fatigue, low-grade fever, and bone or muscle aches for 24–48 hours after the injection.

Serious Risks (Rare):

• Anaphylaxis: As with any vaccine, there is a very small risk of a severe allergic reaction.
• Autoimmunity: Theoretically, the immune system could attack healthy tissues that express low levels of HER2 (like the heart), though significant cardiac toxicity has not been observed with this vaccine.

Research Areas

In the fields of Stem Cell and Regenerative Medicine, nelipepimut-S is being used to study “Immune Surveillance of Cancer Stem Cells.” Cancer stem cells are often resistant to chemotherapy and are the “seeds” that cause a relapse years later. Researchers are investigating if the E75-trained T-cells can hunt down these dormant stem cells in the bone marrow. In 2026, there is also intense focus on “AI-Driven Neoantigen Discovery,” where scientists are using the success of the E75 peptide to design “multi-peptide” vaccines that target five or six different cancer markers at once.

Patient Management and Practical Recommendations

Pre-treatment Requirements:

• HLA Typing: Patients must undergo a blood test to confirm they have the HLA-A2 or HLA-A3 tissue type, as the vaccine only works in these individuals.
• HER2 Testing: Confirmation of HER2-low status ( 1+  or  2+  by IHC) is required.

“Do’s and Don’ts” List:

• DO expect a small, hard lump at the injection site; this “delayed-type hypersensitivity” reaction is a normal part of the vaccination process.
• DO notify your doctor if you are taking high-dose steroids (like Prednisone), as these can “dampen” the immune response and make the vaccine less effective.
• DON’T apply ice or anti-inflammatory creams to the injection site immediately after the shot, as this can interfere with the initial immune activation.
• DON’T miss your 6-month boosters; immune memory for cancer can fade, and the boosters are essential for long-term protection.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Nelipepimut-S plus GM-CSF (NeuVax) is an investigational immunotherapy and is not currently approved for commercial use. Access is restricted to registered clinical trials. Always consult with a qualified oncologist regarding your diagnosis and eligibility for immunotherapy research.

Nelipepimut-S plus GM-CSF vaccine